跳转至内容
Merck

F5016

Sigma-Aldrich

抗-人IgG(Fc特异性)单克隆抗体

clone HP-6017, purified from hybridoma cell culture

别名:

Monoclonal Anti-Human IgG (Fc specific)

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
NACRES:
NA.46

生物源

mouse

共軛

FITC conjugate

抗體表格

purified from hybridoma cell culture

抗體產品種類

secondary antibodies

無性繁殖

HP-6017, monoclonal

形狀

buffered aqueous solution

物種活性

rabbit, sheep, horse (IgG), goat, human

儲存條件

protect from light

技術

dot immunobinding: 1:16
particle immunofluorescence: 1:16

同型

IgG2a

運輸包裝

dry ice

儲存溫度

−20°C

目標翻譯後修改

unmodified

正在寻找类似产品? 访问 产品对比指南

一般說明

Monoclonal Anti-Human IgG (mouse IgG2a isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Immunoglobulins (Igs) belongs immunoglobulin super-family. Each immunoglobin have two heavy (H) and two light (L), held together by disulphide linkages. The light comprises of one variable N-terminal region and a constant C-terminal region. The heavy chain has one variable N-terminal region and three or four constant (CH1-CH4) C-terminal region.

特異性

该抗体对人 IgG 的 Fc 部分具有特异性,并识别所有人 IgG 亚类共有的表位。在 IUIS/WHO 研究中,该抗体被用作 Fc 特异性试剂。

應用

Monoclonal Anti-Human IgG (Fc specific)-FITC antibody produced in mouse has been used in:
  • Fluorescent Dot Immunobinding Assay (F-DIBA)
  • Particle Immunofluorescent Assay (F-IFMA)
  • flow cytometry

生化/生理作用

Digestion of IgG by papain results in generation of fragment antigen binding (Fab) comprising one complete L chain and a variable and CH1 region of H chain. Pepsin digestion of IgG results in fragment crystallisable (fc), containing the H chain constant region. IgG antibody have enormous therapeutic potential and the Fc is for the development of therapeutic antibody. Although the antibody site is located in the terminal end of the human IgG molecule (part of the Fab fragment), the Fc portion has various important functions such as complement fixation, site for rheumatoid factor (autoantibodies directed to Fc), passage through placental membrane and staphylococcus protein A binding.

外觀

Solution in 0.01 M phosphate buffer pH 8.0, containing 1% inactivated bovine serum albumin and 15 mM sodium azide.

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our 产品选型工具.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Resp. Sens. 1 - Skin Sens. 1

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A nonviral carrier for targeted gene delivery to tumor cells
van Zanten J, et al.
Cancer Gene Therapy, 11(2), 156-156 (2004)
Minwoo Kang et al.
Pharmaceutics, 14(7) (2022-07-28)
Immuno-positron emission tomography (PET) has great potential to evaluate the target expression level and therapeutic response for targeted cancer therapy. Immuno-PET imaging with pertuzumab, due to specific recognition in different binding sites of HER2, could be useful for the determination
Martin Pool et al.
European journal of nuclear medicine and molecular imaging, 44(8), 1328-1336 (2017-03-21)
c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging
Dijkers ECF, et al.
Journal of Nuclear Medicine, 50(6), 974-981 (2009)
Eli C F Dijkers et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 50(6), 974-981 (2009-05-16)
The anti-human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is administered to patients with HER2/neu-overexpressing breast cancer. Whole-body noninvasive HER2/neu scintigraphy could help to assess and quantify the HER2/neu expression of all lesions, including nonaccessible metastases. The aims of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门